{
  "paper_id": "PMC10721147",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10721147/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1. Metixene induces apoptotic cell death in brain-metastatic breast cancer cells.",
      "caption": "(A) Viability of BT-474Br and MDA-MB-231Br cells under treatment at different concentrations of metixene for 24 hours and 48 hours. (B) Caspase-3/-7 activity in BT-474Br and MDA-MB-231Br cells under treatment at different concentrations of metixene for 24 hours and 48 hours. (C) Immunofluorescence staining for cleaved caspase-3 after metixene treatment of BT-474Br cells for 2 days. Scale bars: 25 μm. (D) Immunofluorescence staining for cleaved caspase-3 after metixene treatment in MDA-MB-231Br cells for 2 days. Scale bars: 75 μm. (E) Caspase-8/-9 activity in BT-474Br cells under treatment at different concentrations of metixene for 24 hours. (F) Caspase-8/-9 activity in MDA-MB-231Br cells under treatment at different concentrations of metixene for 24 hours. The results in A, B, E, and F are representative of 3 or more technical replicates, and bar graph data show the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 1-way ANOVA with Dunnett’s post hoc test.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/b639ae29fc84/jci-133-161142-g043.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/b639ae29fc84/jci-133-161142-g043.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/b639ae29fc84/jci-133-161142-g043.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/b639ae29fc84/jci-133-161142-g043.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/b639ae29fc84/jci-133-161142-g043.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10721147/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/b639ae29fc84/jci-133-161142-g043.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2. Metixene’s anticancer efficacy decreases the size of mammary fat pad tumors and improves survival in a murine model of metastatic breast cancer.",
      "caption": "(A) Experimental setup of mammary fat pad injections with HCC1954 cells and subsequent treatment with metixene. (B) Metixene treatment at 0.1 mg/kg and 1.0 mg/kg decreased tumor sizes in comparison with controls. (C) Tumor weight at 0.1 mg/kg and 1.0 mg/kg of metixene treatment. (D) Tumor volume at 0.1 mg/kg and 1.0 mg/kg of metixene treatment. (E) H&E (scale bar: 250 μm) and cleaved caspase-3 (scale bar: 50 μm) staining of tumors treated with control, 0.1 mg/kg, and 1.0 mg/kg metixene. Red color indicates cleaved caspase-3; blue color represents DAPI. (F) Percentage of cleaved caspase-3–positive cells (n = 3 per group). (G) Experimental setup for intracardiac injections of MDA-MB-231 cells and subsequent treatment with metixene. (H) Kaplan-Meier curve showing survival of metixene-treated mice versus control mice following intracardiac injection of MDA-MB-231 cells. (I) Experimental setup to determine the bioavailability of metixene in blood and brain tissue. (J) Metixene levels in plasma and brain tissue across time after intraperitoneal administration. **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 1-way ANOVA with Dunnett’s post hoc test (C and F) 2-way ANOVA with Tukey’s post hoc test (D). Survival curves were compared using a log-rank test.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/7b782b90326e/jci-133-161142-g044.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/7b782b90326e/jci-133-161142-g044.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/7b782b90326e/jci-133-161142-g044.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/7b782b90326e/jci-133-161142-g044.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/7b782b90326e/jci-133-161142-g044.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10721147/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/7b782b90326e/jci-133-161142-g044.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3. Metixene improves survival in preclinical models of metastatic brain cancer.",
      "caption": "(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A). Scale bars: 250 μm. (E) Experimental setup for intracarotid artery injection of MDA-MB-231Br cells into nude mice and subsequent treatment with metixene. (F) Kaplan-Meier curve showing survival of metixene-treated mice versus controls upon intracarotid injection of MDA-MB-231Br cells. (G) Histological brain sections upon death of the control mice confirmed the growth of brain tumors as a result of intracarotid injection of MDA-MB-231Br cells. H&E staining of mouse brain shows metastatic tumors (black-framed box), the formation of multiple micrometastases (blue-framed box), and vascular co-option (red-framed box). Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B). Scale bars: 250 μm. Survival curves were compared using a log-rank test. The linear mixed model was fitted for C, and the differences between the 2 groups for each time point were calculated using the least-squares means method and adjusted by Šidák’s method. *P < 0.05 and ***P < 0.001.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/bd255a387f52/jci-133-161142-g045.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/bd255a387f52/jci-133-161142-g045.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/bd255a387f52/jci-133-161142-g045.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/bd255a387f52/jci-133-161142-g045.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/bd255a387f52/jci-133-161142-g045.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10721147/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/bd255a387f52/jci-133-161142-g045.jpg"
    },
    "figure_6": {
      "figure_number": "Figure 6",
      "title": "Figure 6. Metixene induces incomplete autophagy in metastatic brain cancer cells.",
      "caption": "(A) Control and metixene-treated BT-474Br and MDA-MB-231Br cells expressing mCherry-GFP-LC3. Autophagosomes display both GFP and mCherry fluorescence, appearing yellow/green. Autolysosomes showcase mCherry fluorescence only, as GFP was denatured by acidic lysosomes, appearing red. Scale bars: 20 μm. (B) Electron microscopic images of metixene-treated BT-474Br and MDA-MB-231Br cells (white arrows show double-membraned autophagosomes). Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B). Scale bars: 250 μm. Results are representative of 3 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 1-way ANOVA with Dunnett’s post hoc test.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/de1e81c29b7f/jci-133-161142-g048.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/de1e81c29b7f/jci-133-161142-g048.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/de1e81c29b7f/jci-133-161142-g048.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/de1e81c29b7f/jci-133-161142-g048.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F6",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/de1e81c29b7f/jci-133-161142-g048.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10721147/images/figure_6.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/de1e81c29b7f/jci-133-161142-g048.jpg"
    },
    "figure_7": {
      "figure_number": "Figure 7",
      "title": "Figure 7. NDRG1-mediated incomplete autophagy induces apoptotic cell death in metastatic brain cancer cells.",
      "caption": "(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13). Scale bars: 250 μm. Results in A–C are representative of 3 independent experiments. Results in D are representative of 8 technical replicates. Results in E are representative of 4 technical replicates. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by 2-way ANOVA with Šidák’s post hoc test.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/cec9433342ba/jci-133-161142-g049.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/cec9433342ba/jci-133-161142-g049.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/cec9433342ba/jci-133-161142-g049.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/cec9433342ba/jci-133-161142-g049.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F7",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/cec9433342ba/jci-133-161142-g049.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10721147/images/figure_7.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7299/10721147/cec9433342ba/jci-133-161142-g049.jpg"
    }
  },
  "claims": [
    {
      "sentence": "We found that metixene was a potent inhibitor of BCBM regardless of breast cancer subtype, with an IC50 ranging from 9.7 μM to 31.8 μM (Table 2 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI161142DS1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After both 24 and 48 hours of treatment, a dose response was evident in cellular viability assays for both cell lines (Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Flow cytometry results indicated that metixene was inducing cell death in cancer cells (Supplemental Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay was performed to check for caspase-mediated apoptosis, which showed a significant increase in activity that was dependent on dose and time in the BT-474Br and MDA-MB-231Br cells (Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We performed immunofluorescence studies to confirm that metixene induced caspase-3 cleavage in the 2 BCBM cell lines (Figure 1, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After 24 hours, we found that caspase-9 activity was significantly elevated at 10 μM in the BT-474Br cells (P = 0.0055), and at 15 μM in the BT-474Br cells (P < 0.0001) and the MDA-MB-231Br cells (P < 0.0001) (Figure 1, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "When the tumors reached 5 mm in size, the mice were randomized into 3 groups: control (25% captisol, n = 12), metixene (0.1 mg/kg, n = 8), and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times per week (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 6 weeks, the fat pad tumors were collected and analyzed (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor weights were significantly decreased with metixene treatment at 0.1 mg/kg (P < 0.0001) and 1.0 mg/kg (P < 0.0001) (Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor volumes were also significantly reduced with metixene treatment at 0.1 mg/kg (P = 0.0043) and 1.0 mg/kg (P = 0.0004) (Figure 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cleaved caspase-3 staining of tumor sections showed a significant increase in the percentage of cleaved caspase-3–positive cells in the metixene-treated groups at 0.1 mg/kg (P = 0.001) and 1.0 mg/kg (P = 0.0002) (Figure 2, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The treatment regimen involved intraperitoneal administration 3 times per week (Figure 2G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "While the control mice had a median survival of 31 days, the mice receiving metixene had a significantly extended median survival of 38 days (P = 0.0197) (Figure 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Furthermore, we observed no discernible tumor formation in the stomach or liver of these treated mice (Supplemental Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subsequently, 500 μL blood was collected from each mouse, and their brain tissues were harvested for analytical purposes (Figure 2I).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Metixene was completely cleared from the plasma within 3 hours of administration and from brain tissue within a 12-hour time frame (Figure 2J).Metixene improves in vivo survival in preclinical models of metastatic brain cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 10 days, the mice were randomized into 2 groups: control (25% captisol, n = 7) and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times a week (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The metixene-treated mice had a 23% increase in median survival, with a median survival period of 64 days, in contrast to the median survival of 52 days for the control mice (P = 0.0008) (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This finding was consistent with the measurement of the luciferase signal in the brain when the BT-474Br cells were fluorescently labeled and treated with metixene relative to controls after 6 weeks of treatment (P = 0.039) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of the brains of treated mice confirmed that metixene significantly induced caspase-3 cleavage in the established HER2-positive BCBMs in vivo (Figure 3D and Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Ten days after injection of tumor cells, the mice were randomized into 2 groups: control (25% captisol, n = 5) and metixene (1.0 mg/kg, n = 6) and were treated intraperitoneally 3 times per week (Figure 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Therefore, metixene significantly increased survival by 52% in comparison with controls (P = 0.037) (Figure 3F).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological examination of the brains harvested from control-treated mice showed multiple metastases, vascular co-option, and the formation of micrometastases (Figure 3G).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological comparison of brains of control and metixene treated mice showed a decreased tumor burden in the metixene-treated mice (Supplemental Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining showed that cleaved caspase-3 was significantly higher in the BCBM tissue of the metixene-treated mice in vivo (Figure 3H and Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel H",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The difference in body weight of treated and control mice was not significant (Supplemental Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Evaluation of organ tissue, such as the brain, heart, lung, liver, pancreas, kidneys, spleen, stomach, and intestines, revealed no differences in weight or anatomical architecture between the treated and untreated mice (Supplemental Figure 6, B and C).Metixene induces cellular stress and activates macroautophagy signaling pathways.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "RNA levels of either muscarinic (M1–M5) or histamine (H3) receptors did not correlate with the induced cytotoxicity of metixene (Supplemental Figure 7), indicating that the anticancer activity of metixene was not a function of muscarinic or histaminic receptors.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As such, to identify in an unbiased fashion the underlying mechanism of action of metixene, we treated BT-474Br cells with metixene and conducted a reverse-phase protein array (RPPA) analysis to assess the changes in signaling pathways (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Four replicates for each condition (control, 12 hours, and 24 hours) were analyzed and revealed that autophagy is a primary biological mechanism regulated by metixene (P < 0.05) (Figure 4B and Supplemental Figure 8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Among the proteins that exhibited significant changes (with P < 0.001) in expression or phosphorylation, 52 and 26 proteins, respectively were significantly altered (Figure 4, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Other proteins implicated in DNA damage and repair, P53, and cell-cycle control pathways were also affected, indicating cellular stress induction as a result of metixene treatment (Figure 4, E and F, and Supplemental Tables 1 and 2).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Conversion of LC3I to LC3II was shown to increase as early as 10 minutes after metixene treatment (Figure 5A).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Cells treated with the combination of metixene and chloroquine had higher LC3II levels than levels detected in the untreated cells or in the cells treated with either agent alone (Figure 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "This finding was further confirmed with immunofluorescence staining for LC3 (Figure 5C).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Quantification of the area of LC3 puncta per cell showed a significant increase (P < 0.05) upon the addition of chloroquine to metixene in both BT-474Br and MDA-MB-231Br cells (Figure 5, D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunofluorescence staining for LC3 in metixene-treated cells in a dose-dependent manner also showed a significant increase in the area of LC3 puncta per cell as the dose was increased in 2 BCBM cell lines (Supplemental Figure 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The addition of wortmannin, a PI3K inhibitor and an early inhibitor of autophagy flux (24), to metixene led to a decrease in LC3II expression (Supplemental Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "Using a system in which LC3, the marker of autophagosomes, is fused to both GFP and mCherry, we found that metixene-treated BT-474Br and MDA-MB-231 cells contained numerous autophagosomes (yellow/green), which do not bind to lysosomes that degrade their contents (red) (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Electron microscopic analysis of metixene-treated cells at 10 μM showed accumulation of double-membraned autophagic vesicles in the cytoplasm of BT-474Br and MDA-MB-231Br cells (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Similar results were confirmed in primary breast cancer cell lines (Supplemental Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Furthermore, the levels of p62, an autophagy cargo protein that binds other proteins for selective autophagy, increased significantly in BT-474Br (P = 0.0033) and MDA-MB-231Br (P = 0.0043) cells, indicating that the content of autophagic vesicles was not being degraded and that autophagy was incomplete (Figure 6C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of brain samples from control and metixene-treated mice showed that LC3B was significantly higher in metixene-treated samples in both BT-474Br intracranial models and MDA-MB-231Br intracarotid injection models (Figure 6, D and E, and Supplemental Figure 12).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel A",
          "figure_key": "figure_12"
        },
        {
          "figure_number": "Figure 12",
          "panel": "Panel B",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "The expression of NDRG1 and its phosphorylated form, p-NDRG1, increased significantly in a dose-dependent manner in both BT-474Br and MDA-MB-231Br cells after treatment with metixene (Figure 7, A and B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, the significant decrease in p62 levels in NDRG1-KO cells at 5 μM (P = 0.0014), 10 μM (P < 0.0001), and 15 μM (P = 0.0073) indicated that autophagy was being completed in comparison with NDRG1 VC cells (Figure 7C).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "The results showed that NDRG1-KO cells were significantly more viable than control cells at 20 μM (P < 0.0001) (Figure 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay further confirmed that apoptosis was significantly reduced in the NDRG1-KO cells at 10 μM (P = 0.0078) and 15 μM (P < 0.0001) (Figure 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Incomplete autophagy, as indicated by LC3I-to-LC3II conversion and accumulation of p62, preceded NDRG1 phosphorylation and eventual caspase-3 cleavage (Figure 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining for p-NDRG1 in murine brain samples showed that metixene treatment led to significantly higher expression of p-NDRG1 than in control samples (Figure 7G and Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This mechanism of action was consistent in other types of metastatic brain cancer, such as lung cancer and melanoma (Supplemental Figure 14).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We found that stem cell markers, such as SOX2 and OCT4, were downregulated after metixene treatment (Supplemental Figure 15).Discussion\nThe current management of patients with metastatic brain cancer typically includes resection and/or radiation, with a median survival of less than 14 months (27).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "In our work, we found that metixene upregulated NDRG1 expression and phosphorylation, which led to metastasis suppression through incomplete autophagy and apoptosis (Supplemental Figure 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "We found that metixene was a potent inhibitor of BCBM regardless of breast cancer subtype, with an IC50 ranging from 9.7 μM to 31.8 μM (Table 2 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI161142DS1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After both 24 and 48 hours of treatment, a dose response was evident in cellular viability assays for both cell lines (Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Flow cytometry results indicated that metixene was inducing cell death in cancer cells (Supplemental Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay was performed to check for caspase-mediated apoptosis, which showed a significant increase in activity that was dependent on dose and time in the BT-474Br and MDA-MB-231Br cells (Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We performed immunofluorescence studies to confirm that metixene induced caspase-3 cleavage in the 2 BCBM cell lines (Figure 1, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After 24 hours, we found that caspase-9 activity was significantly elevated at 10 μM in the BT-474Br cells (P = 0.0055), and at 15 μM in the BT-474Br cells (P < 0.0001) and the MDA-MB-231Br cells (P < 0.0001) (Figure 1, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "When the tumors reached 5 mm in size, the mice were randomized into 3 groups: control (25% captisol, n = 12), metixene (0.1 mg/kg, n = 8), and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times per week (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 6 weeks, the fat pad tumors were collected and analyzed (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor weights were significantly decreased with metixene treatment at 0.1 mg/kg (P < 0.0001) and 1.0 mg/kg (P < 0.0001) (Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor volumes were also significantly reduced with metixene treatment at 0.1 mg/kg (P = 0.0043) and 1.0 mg/kg (P = 0.0004) (Figure 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cleaved caspase-3 staining of tumor sections showed a significant increase in the percentage of cleaved caspase-3–positive cells in the metixene-treated groups at 0.1 mg/kg (P = 0.001) and 1.0 mg/kg (P = 0.0002) (Figure 2, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The treatment regimen involved intraperitoneal administration 3 times per week (Figure 2G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "While the control mice had a median survival of 31 days, the mice receiving metixene had a significantly extended median survival of 38 days (P = 0.0197) (Figure 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Furthermore, we observed no discernible tumor formation in the stomach or liver of these treated mice (Supplemental Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subsequently, 500 μL blood was collected from each mouse, and their brain tissues were harvested for analytical purposes (Figure 2I).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Metixene was completely cleared from the plasma within 3 hours of administration and from brain tissue within a 12-hour time frame (Figure 2J).Metixene improves in vivo survival in preclinical models of metastatic brain cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 10 days, the mice were randomized into 2 groups: control (25% captisol, n = 7) and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times a week (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The metixene-treated mice had a 23% increase in median survival, with a median survival period of 64 days, in contrast to the median survival of 52 days for the control mice (P = 0.0008) (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This finding was consistent with the measurement of the luciferase signal in the brain when the BT-474Br cells were fluorescently labeled and treated with metixene relative to controls after 6 weeks of treatment (P = 0.039) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of the brains of treated mice confirmed that metixene significantly induced caspase-3 cleavage in the established HER2-positive BCBMs in vivo (Figure 3D and Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Ten days after injection of tumor cells, the mice were randomized into 2 groups: control (25% captisol, n = 5) and metixene (1.0 mg/kg, n = 6) and were treated intraperitoneally 3 times per week (Figure 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Therefore, metixene significantly increased survival by 52% in comparison with controls (P = 0.037) (Figure 3F).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological examination of the brains harvested from control-treated mice showed multiple metastases, vascular co-option, and the formation of micrometastases (Figure 3G).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological comparison of brains of control and metixene treated mice showed a decreased tumor burden in the metixene-treated mice (Supplemental Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining showed that cleaved caspase-3 was significantly higher in the BCBM tissue of the metixene-treated mice in vivo (Figure 3H and Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel H",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The difference in body weight of treated and control mice was not significant (Supplemental Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Evaluation of organ tissue, such as the brain, heart, lung, liver, pancreas, kidneys, spleen, stomach, and intestines, revealed no differences in weight or anatomical architecture between the treated and untreated mice (Supplemental Figure 6, B and C).Metixene induces cellular stress and activates macroautophagy signaling pathways.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "RNA levels of either muscarinic (M1–M5) or histamine (H3) receptors did not correlate with the induced cytotoxicity of metixene (Supplemental Figure 7), indicating that the anticancer activity of metixene was not a function of muscarinic or histaminic receptors.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As such, to identify in an unbiased fashion the underlying mechanism of action of metixene, we treated BT-474Br cells with metixene and conducted a reverse-phase protein array (RPPA) analysis to assess the changes in signaling pathways (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Four replicates for each condition (control, 12 hours, and 24 hours) were analyzed and revealed that autophagy is a primary biological mechanism regulated by metixene (P < 0.05) (Figure 4B and Supplemental Figure 8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Among the proteins that exhibited significant changes (with P < 0.001) in expression or phosphorylation, 52 and 26 proteins, respectively were significantly altered (Figure 4, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Other proteins implicated in DNA damage and repair, P53, and cell-cycle control pathways were also affected, indicating cellular stress induction as a result of metixene treatment (Figure 4, E and F, and Supplemental Tables 1 and 2).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Conversion of LC3I to LC3II was shown to increase as early as 10 minutes after metixene treatment (Figure 5A).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Cells treated with the combination of metixene and chloroquine had higher LC3II levels than levels detected in the untreated cells or in the cells treated with either agent alone (Figure 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "This finding was further confirmed with immunofluorescence staining for LC3 (Figure 5C).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Quantification of the area of LC3 puncta per cell showed a significant increase (P < 0.05) upon the addition of chloroquine to metixene in both BT-474Br and MDA-MB-231Br cells (Figure 5, D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunofluorescence staining for LC3 in metixene-treated cells in a dose-dependent manner also showed a significant increase in the area of LC3 puncta per cell as the dose was increased in 2 BCBM cell lines (Supplemental Figure 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The addition of wortmannin, a PI3K inhibitor and an early inhibitor of autophagy flux (24), to metixene led to a decrease in LC3II expression (Supplemental Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "Using a system in which LC3, the marker of autophagosomes, is fused to both GFP and mCherry, we found that metixene-treated BT-474Br and MDA-MB-231 cells contained numerous autophagosomes (yellow/green), which do not bind to lysosomes that degrade their contents (red) (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Electron microscopic analysis of metixene-treated cells at 10 μM showed accumulation of double-membraned autophagic vesicles in the cytoplasm of BT-474Br and MDA-MB-231Br cells (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Similar results were confirmed in primary breast cancer cell lines (Supplemental Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Furthermore, the levels of p62, an autophagy cargo protein that binds other proteins for selective autophagy, increased significantly in BT-474Br (P = 0.0033) and MDA-MB-231Br (P = 0.0043) cells, indicating that the content of autophagic vesicles was not being degraded and that autophagy was incomplete (Figure 6C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of brain samples from control and metixene-treated mice showed that LC3B was significantly higher in metixene-treated samples in both BT-474Br intracranial models and MDA-MB-231Br intracarotid injection models (Figure 6, D and E, and Supplemental Figure 12).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel A",
          "figure_key": "figure_12"
        },
        {
          "figure_number": "Figure 12",
          "panel": "Panel B",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "The expression of NDRG1 and its phosphorylated form, p-NDRG1, increased significantly in a dose-dependent manner in both BT-474Br and MDA-MB-231Br cells after treatment with metixene (Figure 7, A and B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, the significant decrease in p62 levels in NDRG1-KO cells at 5 μM (P = 0.0014), 10 μM (P < 0.0001), and 15 μM (P = 0.0073) indicated that autophagy was being completed in comparison with NDRG1 VC cells (Figure 7C).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "The results showed that NDRG1-KO cells were significantly more viable than control cells at 20 μM (P < 0.0001) (Figure 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay further confirmed that apoptosis was significantly reduced in the NDRG1-KO cells at 10 μM (P = 0.0078) and 15 μM (P < 0.0001) (Figure 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Incomplete autophagy, as indicated by LC3I-to-LC3II conversion and accumulation of p62, preceded NDRG1 phosphorylation and eventual caspase-3 cleavage (Figure 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining for p-NDRG1 in murine brain samples showed that metixene treatment led to significantly higher expression of p-NDRG1 than in control samples (Figure 7G and Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This mechanism of action was consistent in other types of metastatic brain cancer, such as lung cancer and melanoma (Supplemental Figure 14).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We found that stem cell markers, such as SOX2 and OCT4, were downregulated after metixene treatment (Supplemental Figure 15).Discussion\nThe current management of patients with metastatic brain cancer typically includes resection and/or radiation, with a median survival of less than 14 months (27).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "In our work, we found that metixene upregulated NDRG1 expression and phosphorylation, which led to metastasis suppression through incomplete autophagy and apoptosis (Supplemental Figure 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "We found that metixene was a potent inhibitor of BCBM regardless of breast cancer subtype, with an IC50 ranging from 9.7 μM to 31.8 μM (Table 2 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI161142DS1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After both 24 and 48 hours of treatment, a dose response was evident in cellular viability assays for both cell lines (Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Flow cytometry results indicated that metixene was inducing cell death in cancer cells (Supplemental Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay was performed to check for caspase-mediated apoptosis, which showed a significant increase in activity that was dependent on dose and time in the BT-474Br and MDA-MB-231Br cells (Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We performed immunofluorescence studies to confirm that metixene induced caspase-3 cleavage in the 2 BCBM cell lines (Figure 1, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After 24 hours, we found that caspase-9 activity was significantly elevated at 10 μM in the BT-474Br cells (P = 0.0055), and at 15 μM in the BT-474Br cells (P < 0.0001) and the MDA-MB-231Br cells (P < 0.0001) (Figure 1, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "When the tumors reached 5 mm in size, the mice were randomized into 3 groups: control (25% captisol, n = 12), metixene (0.1 mg/kg, n = 8), and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times per week (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 6 weeks, the fat pad tumors were collected and analyzed (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor weights were significantly decreased with metixene treatment at 0.1 mg/kg (P < 0.0001) and 1.0 mg/kg (P < 0.0001) (Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor volumes were also significantly reduced with metixene treatment at 0.1 mg/kg (P = 0.0043) and 1.0 mg/kg (P = 0.0004) (Figure 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cleaved caspase-3 staining of tumor sections showed a significant increase in the percentage of cleaved caspase-3–positive cells in the metixene-treated groups at 0.1 mg/kg (P = 0.001) and 1.0 mg/kg (P = 0.0002) (Figure 2, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The treatment regimen involved intraperitoneal administration 3 times per week (Figure 2G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "While the control mice had a median survival of 31 days, the mice receiving metixene had a significantly extended median survival of 38 days (P = 0.0197) (Figure 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Furthermore, we observed no discernible tumor formation in the stomach or liver of these treated mice (Supplemental Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subsequently, 500 μL blood was collected from each mouse, and their brain tissues were harvested for analytical purposes (Figure 2I).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Metixene was completely cleared from the plasma within 3 hours of administration and from brain tissue within a 12-hour time frame (Figure 2J).Metixene improves in vivo survival in preclinical models of metastatic brain cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 10 days, the mice were randomized into 2 groups: control (25% captisol, n = 7) and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times a week (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The metixene-treated mice had a 23% increase in median survival, with a median survival period of 64 days, in contrast to the median survival of 52 days for the control mice (P = 0.0008) (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This finding was consistent with the measurement of the luciferase signal in the brain when the BT-474Br cells were fluorescently labeled and treated with metixene relative to controls after 6 weeks of treatment (P = 0.039) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of the brains of treated mice confirmed that metixene significantly induced caspase-3 cleavage in the established HER2-positive BCBMs in vivo (Figure 3D and Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Ten days after injection of tumor cells, the mice were randomized into 2 groups: control (25% captisol, n = 5) and metixene (1.0 mg/kg, n = 6) and were treated intraperitoneally 3 times per week (Figure 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Therefore, metixene significantly increased survival by 52% in comparison with controls (P = 0.037) (Figure 3F).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological examination of the brains harvested from control-treated mice showed multiple metastases, vascular co-option, and the formation of micrometastases (Figure 3G).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological comparison of brains of control and metixene treated mice showed a decreased tumor burden in the metixene-treated mice (Supplemental Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining showed that cleaved caspase-3 was significantly higher in the BCBM tissue of the metixene-treated mice in vivo (Figure 3H and Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel H",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The difference in body weight of treated and control mice was not significant (Supplemental Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Evaluation of organ tissue, such as the brain, heart, lung, liver, pancreas, kidneys, spleen, stomach, and intestines, revealed no differences in weight or anatomical architecture between the treated and untreated mice (Supplemental Figure 6, B and C).Metixene induces cellular stress and activates macroautophagy signaling pathways.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "RNA levels of either muscarinic (M1–M5) or histamine (H3) receptors did not correlate with the induced cytotoxicity of metixene (Supplemental Figure 7), indicating that the anticancer activity of metixene was not a function of muscarinic or histaminic receptors.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As such, to identify in an unbiased fashion the underlying mechanism of action of metixene, we treated BT-474Br cells with metixene and conducted a reverse-phase protein array (RPPA) analysis to assess the changes in signaling pathways (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Four replicates for each condition (control, 12 hours, and 24 hours) were analyzed and revealed that autophagy is a primary biological mechanism regulated by metixene (P < 0.05) (Figure 4B and Supplemental Figure 8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Among the proteins that exhibited significant changes (with P < 0.001) in expression or phosphorylation, 52 and 26 proteins, respectively were significantly altered (Figure 4, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Other proteins implicated in DNA damage and repair, P53, and cell-cycle control pathways were also affected, indicating cellular stress induction as a result of metixene treatment (Figure 4, E and F, and Supplemental Tables 1 and 2).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Conversion of LC3I to LC3II was shown to increase as early as 10 minutes after metixene treatment (Figure 5A).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Cells treated with the combination of metixene and chloroquine had higher LC3II levels than levels detected in the untreated cells or in the cells treated with either agent alone (Figure 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "This finding was further confirmed with immunofluorescence staining for LC3 (Figure 5C).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Quantification of the area of LC3 puncta per cell showed a significant increase (P < 0.05) upon the addition of chloroquine to metixene in both BT-474Br and MDA-MB-231Br cells (Figure 5, D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunofluorescence staining for LC3 in metixene-treated cells in a dose-dependent manner also showed a significant increase in the area of LC3 puncta per cell as the dose was increased in 2 BCBM cell lines (Supplemental Figure 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The addition of wortmannin, a PI3K inhibitor and an early inhibitor of autophagy flux (24), to metixene led to a decrease in LC3II expression (Supplemental Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "Using a system in which LC3, the marker of autophagosomes, is fused to both GFP and mCherry, we found that metixene-treated BT-474Br and MDA-MB-231 cells contained numerous autophagosomes (yellow/green), which do not bind to lysosomes that degrade their contents (red) (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Electron microscopic analysis of metixene-treated cells at 10 μM showed accumulation of double-membraned autophagic vesicles in the cytoplasm of BT-474Br and MDA-MB-231Br cells (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Similar results were confirmed in primary breast cancer cell lines (Supplemental Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Furthermore, the levels of p62, an autophagy cargo protein that binds other proteins for selective autophagy, increased significantly in BT-474Br (P = 0.0033) and MDA-MB-231Br (P = 0.0043) cells, indicating that the content of autophagic vesicles was not being degraded and that autophagy was incomplete (Figure 6C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of brain samples from control and metixene-treated mice showed that LC3B was significantly higher in metixene-treated samples in both BT-474Br intracranial models and MDA-MB-231Br intracarotid injection models (Figure 6, D and E, and Supplemental Figure 12).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel A",
          "figure_key": "figure_12"
        },
        {
          "figure_number": "Figure 12",
          "panel": "Panel B",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "The expression of NDRG1 and its phosphorylated form, p-NDRG1, increased significantly in a dose-dependent manner in both BT-474Br and MDA-MB-231Br cells after treatment with metixene (Figure 7, A and B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, the significant decrease in p62 levels in NDRG1-KO cells at 5 μM (P = 0.0014), 10 μM (P < 0.0001), and 15 μM (P = 0.0073) indicated that autophagy was being completed in comparison with NDRG1 VC cells (Figure 7C).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "The results showed that NDRG1-KO cells were significantly more viable than control cells at 20 μM (P < 0.0001) (Figure 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay further confirmed that apoptosis was significantly reduced in the NDRG1-KO cells at 10 μM (P = 0.0078) and 15 μM (P < 0.0001) (Figure 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Incomplete autophagy, as indicated by LC3I-to-LC3II conversion and accumulation of p62, preceded NDRG1 phosphorylation and eventual caspase-3 cleavage (Figure 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining for p-NDRG1 in murine brain samples showed that metixene treatment led to significantly higher expression of p-NDRG1 than in control samples (Figure 7G and Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This mechanism of action was consistent in other types of metastatic brain cancer, such as lung cancer and melanoma (Supplemental Figure 14).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We found that stem cell markers, such as SOX2 and OCT4, were downregulated after metixene treatment (Supplemental Figure 15).Discussion\nThe current management of patients with metastatic brain cancer typically includes resection and/or radiation, with a median survival of less than 14 months (27).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "In our work, we found that metixene upregulated NDRG1 expression and phosphorylation, which led to metastasis suppression through incomplete autophagy and apoptosis (Supplemental Figure 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "We found that metixene was a potent inhibitor of BCBM regardless of breast cancer subtype, with an IC50 ranging from 9.7 μM to 31.8 μM (Table 2 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI161142DS1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After both 24 and 48 hours of treatment, a dose response was evident in cellular viability assays for both cell lines (Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Flow cytometry results indicated that metixene was inducing cell death in cancer cells (Supplemental Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay was performed to check for caspase-mediated apoptosis, which showed a significant increase in activity that was dependent on dose and time in the BT-474Br and MDA-MB-231Br cells (Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We performed immunofluorescence studies to confirm that metixene induced caspase-3 cleavage in the 2 BCBM cell lines (Figure 1, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After 24 hours, we found that caspase-9 activity was significantly elevated at 10 μM in the BT-474Br cells (P = 0.0055), and at 15 μM in the BT-474Br cells (P < 0.0001) and the MDA-MB-231Br cells (P < 0.0001) (Figure 1, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "When the tumors reached 5 mm in size, the mice were randomized into 3 groups: control (25% captisol, n = 12), metixene (0.1 mg/kg, n = 8), and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times per week (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 6 weeks, the fat pad tumors were collected and analyzed (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor weights were significantly decreased with metixene treatment at 0.1 mg/kg (P < 0.0001) and 1.0 mg/kg (P < 0.0001) (Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor volumes were also significantly reduced with metixene treatment at 0.1 mg/kg (P = 0.0043) and 1.0 mg/kg (P = 0.0004) (Figure 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cleaved caspase-3 staining of tumor sections showed a significant increase in the percentage of cleaved caspase-3–positive cells in the metixene-treated groups at 0.1 mg/kg (P = 0.001) and 1.0 mg/kg (P = 0.0002) (Figure 2, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The treatment regimen involved intraperitoneal administration 3 times per week (Figure 2G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "While the control mice had a median survival of 31 days, the mice receiving metixene had a significantly extended median survival of 38 days (P = 0.0197) (Figure 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Furthermore, we observed no discernible tumor formation in the stomach or liver of these treated mice (Supplemental Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subsequently, 500 μL blood was collected from each mouse, and their brain tissues were harvested for analytical purposes (Figure 2I).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Metixene was completely cleared from the plasma within 3 hours of administration and from brain tissue within a 12-hour time frame (Figure 2J).Metixene improves in vivo survival in preclinical models of metastatic brain cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 10 days, the mice were randomized into 2 groups: control (25% captisol, n = 7) and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times a week (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The metixene-treated mice had a 23% increase in median survival, with a median survival period of 64 days, in contrast to the median survival of 52 days for the control mice (P = 0.0008) (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This finding was consistent with the measurement of the luciferase signal in the brain when the BT-474Br cells were fluorescently labeled and treated with metixene relative to controls after 6 weeks of treatment (P = 0.039) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of the brains of treated mice confirmed that metixene significantly induced caspase-3 cleavage in the established HER2-positive BCBMs in vivo (Figure 3D and Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Ten days after injection of tumor cells, the mice were randomized into 2 groups: control (25% captisol, n = 5) and metixene (1.0 mg/kg, n = 6) and were treated intraperitoneally 3 times per week (Figure 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Therefore, metixene significantly increased survival by 52% in comparison with controls (P = 0.037) (Figure 3F).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological examination of the brains harvested from control-treated mice showed multiple metastases, vascular co-option, and the formation of micrometastases (Figure 3G).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological comparison of brains of control and metixene treated mice showed a decreased tumor burden in the metixene-treated mice (Supplemental Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining showed that cleaved caspase-3 was significantly higher in the BCBM tissue of the metixene-treated mice in vivo (Figure 3H and Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel H",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The difference in body weight of treated and control mice was not significant (Supplemental Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Evaluation of organ tissue, such as the brain, heart, lung, liver, pancreas, kidneys, spleen, stomach, and intestines, revealed no differences in weight or anatomical architecture between the treated and untreated mice (Supplemental Figure 6, B and C).Metixene induces cellular stress and activates macroautophagy signaling pathways.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "RNA levels of either muscarinic (M1–M5) or histamine (H3) receptors did not correlate with the induced cytotoxicity of metixene (Supplemental Figure 7), indicating that the anticancer activity of metixene was not a function of muscarinic or histaminic receptors.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As such, to identify in an unbiased fashion the underlying mechanism of action of metixene, we treated BT-474Br cells with metixene and conducted a reverse-phase protein array (RPPA) analysis to assess the changes in signaling pathways (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Four replicates for each condition (control, 12 hours, and 24 hours) were analyzed and revealed that autophagy is a primary biological mechanism regulated by metixene (P < 0.05) (Figure 4B and Supplemental Figure 8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Among the proteins that exhibited significant changes (with P < 0.001) in expression or phosphorylation, 52 and 26 proteins, respectively were significantly altered (Figure 4, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Other proteins implicated in DNA damage and repair, P53, and cell-cycle control pathways were also affected, indicating cellular stress induction as a result of metixene treatment (Figure 4, E and F, and Supplemental Tables 1 and 2).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Conversion of LC3I to LC3II was shown to increase as early as 10 minutes after metixene treatment (Figure 5A).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Cells treated with the combination of metixene and chloroquine had higher LC3II levels than levels detected in the untreated cells or in the cells treated with either agent alone (Figure 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "This finding was further confirmed with immunofluorescence staining for LC3 (Figure 5C).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Quantification of the area of LC3 puncta per cell showed a significant increase (P < 0.05) upon the addition of chloroquine to metixene in both BT-474Br and MDA-MB-231Br cells (Figure 5, D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunofluorescence staining for LC3 in metixene-treated cells in a dose-dependent manner also showed a significant increase in the area of LC3 puncta per cell as the dose was increased in 2 BCBM cell lines (Supplemental Figure 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The addition of wortmannin, a PI3K inhibitor and an early inhibitor of autophagy flux (24), to metixene led to a decrease in LC3II expression (Supplemental Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "Using a system in which LC3, the marker of autophagosomes, is fused to both GFP and mCherry, we found that metixene-treated BT-474Br and MDA-MB-231 cells contained numerous autophagosomes (yellow/green), which do not bind to lysosomes that degrade their contents (red) (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Electron microscopic analysis of metixene-treated cells at 10 μM showed accumulation of double-membraned autophagic vesicles in the cytoplasm of BT-474Br and MDA-MB-231Br cells (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Similar results were confirmed in primary breast cancer cell lines (Supplemental Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Furthermore, the levels of p62, an autophagy cargo protein that binds other proteins for selective autophagy, increased significantly in BT-474Br (P = 0.0033) and MDA-MB-231Br (P = 0.0043) cells, indicating that the content of autophagic vesicles was not being degraded and that autophagy was incomplete (Figure 6C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of brain samples from control and metixene-treated mice showed that LC3B was significantly higher in metixene-treated samples in both BT-474Br intracranial models and MDA-MB-231Br intracarotid injection models (Figure 6, D and E, and Supplemental Figure 12).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel A",
          "figure_key": "figure_12"
        },
        {
          "figure_number": "Figure 12",
          "panel": "Panel B",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "The expression of NDRG1 and its phosphorylated form, p-NDRG1, increased significantly in a dose-dependent manner in both BT-474Br and MDA-MB-231Br cells after treatment with metixene (Figure 7, A and B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, the significant decrease in p62 levels in NDRG1-KO cells at 5 μM (P = 0.0014), 10 μM (P < 0.0001), and 15 μM (P = 0.0073) indicated that autophagy was being completed in comparison with NDRG1 VC cells (Figure 7C).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "The results showed that NDRG1-KO cells were significantly more viable than control cells at 20 μM (P < 0.0001) (Figure 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay further confirmed that apoptosis was significantly reduced in the NDRG1-KO cells at 10 μM (P = 0.0078) and 15 μM (P < 0.0001) (Figure 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Incomplete autophagy, as indicated by LC3I-to-LC3II conversion and accumulation of p62, preceded NDRG1 phosphorylation and eventual caspase-3 cleavage (Figure 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining for p-NDRG1 in murine brain samples showed that metixene treatment led to significantly higher expression of p-NDRG1 than in control samples (Figure 7G and Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This mechanism of action was consistent in other types of metastatic brain cancer, such as lung cancer and melanoma (Supplemental Figure 14).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We found that stem cell markers, such as SOX2 and OCT4, were downregulated after metixene treatment (Supplemental Figure 15).Discussion\nThe current management of patients with metastatic brain cancer typically includes resection and/or radiation, with a median survival of less than 14 months (27).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "In our work, we found that metixene upregulated NDRG1 expression and phosphorylation, which led to metastasis suppression through incomplete autophagy and apoptosis (Supplemental Figure 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "We found that metixene was a potent inhibitor of BCBM regardless of breast cancer subtype, with an IC50 ranging from 9.7 μM to 31.8 μM (Table 2 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI161142DS1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After both 24 and 48 hours of treatment, a dose response was evident in cellular viability assays for both cell lines (Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Flow cytometry results indicated that metixene was inducing cell death in cancer cells (Supplemental Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay was performed to check for caspase-mediated apoptosis, which showed a significant increase in activity that was dependent on dose and time in the BT-474Br and MDA-MB-231Br cells (Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We performed immunofluorescence studies to confirm that metixene induced caspase-3 cleavage in the 2 BCBM cell lines (Figure 1, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After 24 hours, we found that caspase-9 activity was significantly elevated at 10 μM in the BT-474Br cells (P = 0.0055), and at 15 μM in the BT-474Br cells (P < 0.0001) and the MDA-MB-231Br cells (P < 0.0001) (Figure 1, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "When the tumors reached 5 mm in size, the mice were randomized into 3 groups: control (25% captisol, n = 12), metixene (0.1 mg/kg, n = 8), and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times per week (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 6 weeks, the fat pad tumors were collected and analyzed (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor weights were significantly decreased with metixene treatment at 0.1 mg/kg (P < 0.0001) and 1.0 mg/kg (P < 0.0001) (Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor volumes were also significantly reduced with metixene treatment at 0.1 mg/kg (P = 0.0043) and 1.0 mg/kg (P = 0.0004) (Figure 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cleaved caspase-3 staining of tumor sections showed a significant increase in the percentage of cleaved caspase-3–positive cells in the metixene-treated groups at 0.1 mg/kg (P = 0.001) and 1.0 mg/kg (P = 0.0002) (Figure 2, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The treatment regimen involved intraperitoneal administration 3 times per week (Figure 2G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "While the control mice had a median survival of 31 days, the mice receiving metixene had a significantly extended median survival of 38 days (P = 0.0197) (Figure 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Furthermore, we observed no discernible tumor formation in the stomach or liver of these treated mice (Supplemental Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subsequently, 500 μL blood was collected from each mouse, and their brain tissues were harvested for analytical purposes (Figure 2I).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Metixene was completely cleared from the plasma within 3 hours of administration and from brain tissue within a 12-hour time frame (Figure 2J).Metixene improves in vivo survival in preclinical models of metastatic brain cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 10 days, the mice were randomized into 2 groups: control (25% captisol, n = 7) and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times a week (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The metixene-treated mice had a 23% increase in median survival, with a median survival period of 64 days, in contrast to the median survival of 52 days for the control mice (P = 0.0008) (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This finding was consistent with the measurement of the luciferase signal in the brain when the BT-474Br cells were fluorescently labeled and treated with metixene relative to controls after 6 weeks of treatment (P = 0.039) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of the brains of treated mice confirmed that metixene significantly induced caspase-3 cleavage in the established HER2-positive BCBMs in vivo (Figure 3D and Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Ten days after injection of tumor cells, the mice were randomized into 2 groups: control (25% captisol, n = 5) and metixene (1.0 mg/kg, n = 6) and were treated intraperitoneally 3 times per week (Figure 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Therefore, metixene significantly increased survival by 52% in comparison with controls (P = 0.037) (Figure 3F).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological examination of the brains harvested from control-treated mice showed multiple metastases, vascular co-option, and the formation of micrometastases (Figure 3G).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological comparison of brains of control and metixene treated mice showed a decreased tumor burden in the metixene-treated mice (Supplemental Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining showed that cleaved caspase-3 was significantly higher in the BCBM tissue of the metixene-treated mice in vivo (Figure 3H and Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel H",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The difference in body weight of treated and control mice was not significant (Supplemental Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Evaluation of organ tissue, such as the brain, heart, lung, liver, pancreas, kidneys, spleen, stomach, and intestines, revealed no differences in weight or anatomical architecture between the treated and untreated mice (Supplemental Figure 6, B and C).Metixene induces cellular stress and activates macroautophagy signaling pathways.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "RNA levels of either muscarinic (M1–M5) or histamine (H3) receptors did not correlate with the induced cytotoxicity of metixene (Supplemental Figure 7), indicating that the anticancer activity of metixene was not a function of muscarinic or histaminic receptors.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As such, to identify in an unbiased fashion the underlying mechanism of action of metixene, we treated BT-474Br cells with metixene and conducted a reverse-phase protein array (RPPA) analysis to assess the changes in signaling pathways (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Four replicates for each condition (control, 12 hours, and 24 hours) were analyzed and revealed that autophagy is a primary biological mechanism regulated by metixene (P < 0.05) (Figure 4B and Supplemental Figure 8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Among the proteins that exhibited significant changes (with P < 0.001) in expression or phosphorylation, 52 and 26 proteins, respectively were significantly altered (Figure 4, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Other proteins implicated in DNA damage and repair, P53, and cell-cycle control pathways were also affected, indicating cellular stress induction as a result of metixene treatment (Figure 4, E and F, and Supplemental Tables 1 and 2).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Conversion of LC3I to LC3II was shown to increase as early as 10 minutes after metixene treatment (Figure 5A).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Cells treated with the combination of metixene and chloroquine had higher LC3II levels than levels detected in the untreated cells or in the cells treated with either agent alone (Figure 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "This finding was further confirmed with immunofluorescence staining for LC3 (Figure 5C).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Quantification of the area of LC3 puncta per cell showed a significant increase (P < 0.05) upon the addition of chloroquine to metixene in both BT-474Br and MDA-MB-231Br cells (Figure 5, D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunofluorescence staining for LC3 in metixene-treated cells in a dose-dependent manner also showed a significant increase in the area of LC3 puncta per cell as the dose was increased in 2 BCBM cell lines (Supplemental Figure 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The addition of wortmannin, a PI3K inhibitor and an early inhibitor of autophagy flux (24), to metixene led to a decrease in LC3II expression (Supplemental Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "Using a system in which LC3, the marker of autophagosomes, is fused to both GFP and mCherry, we found that metixene-treated BT-474Br and MDA-MB-231 cells contained numerous autophagosomes (yellow/green), which do not bind to lysosomes that degrade their contents (red) (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Electron microscopic analysis of metixene-treated cells at 10 μM showed accumulation of double-membraned autophagic vesicles in the cytoplasm of BT-474Br and MDA-MB-231Br cells (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Similar results were confirmed in primary breast cancer cell lines (Supplemental Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Furthermore, the levels of p62, an autophagy cargo protein that binds other proteins for selective autophagy, increased significantly in BT-474Br (P = 0.0033) and MDA-MB-231Br (P = 0.0043) cells, indicating that the content of autophagic vesicles was not being degraded and that autophagy was incomplete (Figure 6C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of brain samples from control and metixene-treated mice showed that LC3B was significantly higher in metixene-treated samples in both BT-474Br intracranial models and MDA-MB-231Br intracarotid injection models (Figure 6, D and E, and Supplemental Figure 12).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel A",
          "figure_key": "figure_12"
        },
        {
          "figure_number": "Figure 12",
          "panel": "Panel B",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "The expression of NDRG1 and its phosphorylated form, p-NDRG1, increased significantly in a dose-dependent manner in both BT-474Br and MDA-MB-231Br cells after treatment with metixene (Figure 7, A and B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, the significant decrease in p62 levels in NDRG1-KO cells at 5 μM (P = 0.0014), 10 μM (P < 0.0001), and 15 μM (P = 0.0073) indicated that autophagy was being completed in comparison with NDRG1 VC cells (Figure 7C).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "The results showed that NDRG1-KO cells were significantly more viable than control cells at 20 μM (P < 0.0001) (Figure 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay further confirmed that apoptosis was significantly reduced in the NDRG1-KO cells at 10 μM (P = 0.0078) and 15 μM (P < 0.0001) (Figure 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Incomplete autophagy, as indicated by LC3I-to-LC3II conversion and accumulation of p62, preceded NDRG1 phosphorylation and eventual caspase-3 cleavage (Figure 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining for p-NDRG1 in murine brain samples showed that metixene treatment led to significantly higher expression of p-NDRG1 than in control samples (Figure 7G and Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This mechanism of action was consistent in other types of metastatic brain cancer, such as lung cancer and melanoma (Supplemental Figure 14).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We found that stem cell markers, such as SOX2 and OCT4, were downregulated after metixene treatment (Supplemental Figure 15).Discussion\nThe current management of patients with metastatic brain cancer typically includes resection and/or radiation, with a median survival of less than 14 months (27).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "In our work, we found that metixene upregulated NDRG1 expression and phosphorylation, which led to metastasis suppression through incomplete autophagy and apoptosis (Supplemental Figure 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "We found that metixene was a potent inhibitor of BCBM regardless of breast cancer subtype, with an IC50 ranging from 9.7 μM to 31.8 μM (Table 2 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI161142DS1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After both 24 and 48 hours of treatment, a dose response was evident in cellular viability assays for both cell lines (Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Flow cytometry results indicated that metixene was inducing cell death in cancer cells (Supplemental Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay was performed to check for caspase-mediated apoptosis, which showed a significant increase in activity that was dependent on dose and time in the BT-474Br and MDA-MB-231Br cells (Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We performed immunofluorescence studies to confirm that metixene induced caspase-3 cleavage in the 2 BCBM cell lines (Figure 1, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After 24 hours, we found that caspase-9 activity was significantly elevated at 10 μM in the BT-474Br cells (P = 0.0055), and at 15 μM in the BT-474Br cells (P < 0.0001) and the MDA-MB-231Br cells (P < 0.0001) (Figure 1, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "When the tumors reached 5 mm in size, the mice were randomized into 3 groups: control (25% captisol, n = 12), metixene (0.1 mg/kg, n = 8), and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times per week (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 6 weeks, the fat pad tumors were collected and analyzed (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor weights were significantly decreased with metixene treatment at 0.1 mg/kg (P < 0.0001) and 1.0 mg/kg (P < 0.0001) (Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor volumes were also significantly reduced with metixene treatment at 0.1 mg/kg (P = 0.0043) and 1.0 mg/kg (P = 0.0004) (Figure 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cleaved caspase-3 staining of tumor sections showed a significant increase in the percentage of cleaved caspase-3–positive cells in the metixene-treated groups at 0.1 mg/kg (P = 0.001) and 1.0 mg/kg (P = 0.0002) (Figure 2, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The treatment regimen involved intraperitoneal administration 3 times per week (Figure 2G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "While the control mice had a median survival of 31 days, the mice receiving metixene had a significantly extended median survival of 38 days (P = 0.0197) (Figure 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Furthermore, we observed no discernible tumor formation in the stomach or liver of these treated mice (Supplemental Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subsequently, 500 μL blood was collected from each mouse, and their brain tissues were harvested for analytical purposes (Figure 2I).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Metixene was completely cleared from the plasma within 3 hours of administration and from brain tissue within a 12-hour time frame (Figure 2J).Metixene improves in vivo survival in preclinical models of metastatic brain cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 10 days, the mice were randomized into 2 groups: control (25% captisol, n = 7) and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times a week (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The metixene-treated mice had a 23% increase in median survival, with a median survival period of 64 days, in contrast to the median survival of 52 days for the control mice (P = 0.0008) (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This finding was consistent with the measurement of the luciferase signal in the brain when the BT-474Br cells were fluorescently labeled and treated with metixene relative to controls after 6 weeks of treatment (P = 0.039) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of the brains of treated mice confirmed that metixene significantly induced caspase-3 cleavage in the established HER2-positive BCBMs in vivo (Figure 3D and Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Ten days after injection of tumor cells, the mice were randomized into 2 groups: control (25% captisol, n = 5) and metixene (1.0 mg/kg, n = 6) and were treated intraperitoneally 3 times per week (Figure 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Therefore, metixene significantly increased survival by 52% in comparison with controls (P = 0.037) (Figure 3F).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological examination of the brains harvested from control-treated mice showed multiple metastases, vascular co-option, and the formation of micrometastases (Figure 3G).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological comparison of brains of control and metixene treated mice showed a decreased tumor burden in the metixene-treated mice (Supplemental Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining showed that cleaved caspase-3 was significantly higher in the BCBM tissue of the metixene-treated mice in vivo (Figure 3H and Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel H",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The difference in body weight of treated and control mice was not significant (Supplemental Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Evaluation of organ tissue, such as the brain, heart, lung, liver, pancreas, kidneys, spleen, stomach, and intestines, revealed no differences in weight or anatomical architecture between the treated and untreated mice (Supplemental Figure 6, B and C).Metixene induces cellular stress and activates macroautophagy signaling pathways.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "RNA levels of either muscarinic (M1–M5) or histamine (H3) receptors did not correlate with the induced cytotoxicity of metixene (Supplemental Figure 7), indicating that the anticancer activity of metixene was not a function of muscarinic or histaminic receptors.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As such, to identify in an unbiased fashion the underlying mechanism of action of metixene, we treated BT-474Br cells with metixene and conducted a reverse-phase protein array (RPPA) analysis to assess the changes in signaling pathways (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Four replicates for each condition (control, 12 hours, and 24 hours) were analyzed and revealed that autophagy is a primary biological mechanism regulated by metixene (P < 0.05) (Figure 4B and Supplemental Figure 8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Among the proteins that exhibited significant changes (with P < 0.001) in expression or phosphorylation, 52 and 26 proteins, respectively were significantly altered (Figure 4, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Other proteins implicated in DNA damage and repair, P53, and cell-cycle control pathways were also affected, indicating cellular stress induction as a result of metixene treatment (Figure 4, E and F, and Supplemental Tables 1 and 2).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Conversion of LC3I to LC3II was shown to increase as early as 10 minutes after metixene treatment (Figure 5A).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Cells treated with the combination of metixene and chloroquine had higher LC3II levels than levels detected in the untreated cells or in the cells treated with either agent alone (Figure 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "This finding was further confirmed with immunofluorescence staining for LC3 (Figure 5C).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Quantification of the area of LC3 puncta per cell showed a significant increase (P < 0.05) upon the addition of chloroquine to metixene in both BT-474Br and MDA-MB-231Br cells (Figure 5, D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunofluorescence staining for LC3 in metixene-treated cells in a dose-dependent manner also showed a significant increase in the area of LC3 puncta per cell as the dose was increased in 2 BCBM cell lines (Supplemental Figure 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The addition of wortmannin, a PI3K inhibitor and an early inhibitor of autophagy flux (24), to metixene led to a decrease in LC3II expression (Supplemental Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "Using a system in which LC3, the marker of autophagosomes, is fused to both GFP and mCherry, we found that metixene-treated BT-474Br and MDA-MB-231 cells contained numerous autophagosomes (yellow/green), which do not bind to lysosomes that degrade their contents (red) (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Electron microscopic analysis of metixene-treated cells at 10 μM showed accumulation of double-membraned autophagic vesicles in the cytoplasm of BT-474Br and MDA-MB-231Br cells (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Similar results were confirmed in primary breast cancer cell lines (Supplemental Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Furthermore, the levels of p62, an autophagy cargo protein that binds other proteins for selective autophagy, increased significantly in BT-474Br (P = 0.0033) and MDA-MB-231Br (P = 0.0043) cells, indicating that the content of autophagic vesicles was not being degraded and that autophagy was incomplete (Figure 6C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of brain samples from control and metixene-treated mice showed that LC3B was significantly higher in metixene-treated samples in both BT-474Br intracranial models and MDA-MB-231Br intracarotid injection models (Figure 6, D and E, and Supplemental Figure 12).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel A",
          "figure_key": "figure_12"
        },
        {
          "figure_number": "Figure 12",
          "panel": "Panel B",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "The expression of NDRG1 and its phosphorylated form, p-NDRG1, increased significantly in a dose-dependent manner in both BT-474Br and MDA-MB-231Br cells after treatment with metixene (Figure 7, A and B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, the significant decrease in p62 levels in NDRG1-KO cells at 5 μM (P = 0.0014), 10 μM (P < 0.0001), and 15 μM (P = 0.0073) indicated that autophagy was being completed in comparison with NDRG1 VC cells (Figure 7C).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "The results showed that NDRG1-KO cells were significantly more viable than control cells at 20 μM (P < 0.0001) (Figure 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay further confirmed that apoptosis was significantly reduced in the NDRG1-KO cells at 10 μM (P = 0.0078) and 15 μM (P < 0.0001) (Figure 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Incomplete autophagy, as indicated by LC3I-to-LC3II conversion and accumulation of p62, preceded NDRG1 phosphorylation and eventual caspase-3 cleavage (Figure 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining for p-NDRG1 in murine brain samples showed that metixene treatment led to significantly higher expression of p-NDRG1 than in control samples (Figure 7G and Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This mechanism of action was consistent in other types of metastatic brain cancer, such as lung cancer and melanoma (Supplemental Figure 14).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We found that stem cell markers, such as SOX2 and OCT4, were downregulated after metixene treatment (Supplemental Figure 15).Discussion\nThe current management of patients with metastatic brain cancer typically includes resection and/or radiation, with a median survival of less than 14 months (27).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "In our work, we found that metixene upregulated NDRG1 expression and phosphorylation, which led to metastasis suppression through incomplete autophagy and apoptosis (Supplemental Figure 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "We found that metixene was a potent inhibitor of BCBM regardless of breast cancer subtype, with an IC50 ranging from 9.7 μM to 31.8 μM (Table 2 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI161142DS1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After both 24 and 48 hours of treatment, a dose response was evident in cellular viability assays for both cell lines (Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Flow cytometry results indicated that metixene was inducing cell death in cancer cells (Supplemental Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay was performed to check for caspase-mediated apoptosis, which showed a significant increase in activity that was dependent on dose and time in the BT-474Br and MDA-MB-231Br cells (Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We performed immunofluorescence studies to confirm that metixene induced caspase-3 cleavage in the 2 BCBM cell lines (Figure 1, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After 24 hours, we found that caspase-9 activity was significantly elevated at 10 μM in the BT-474Br cells (P = 0.0055), and at 15 μM in the BT-474Br cells (P < 0.0001) and the MDA-MB-231Br cells (P < 0.0001) (Figure 1, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "When the tumors reached 5 mm in size, the mice were randomized into 3 groups: control (25% captisol, n = 12), metixene (0.1 mg/kg, n = 8), and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times per week (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 6 weeks, the fat pad tumors were collected and analyzed (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor weights were significantly decreased with metixene treatment at 0.1 mg/kg (P < 0.0001) and 1.0 mg/kg (P < 0.0001) (Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor volumes were also significantly reduced with metixene treatment at 0.1 mg/kg (P = 0.0043) and 1.0 mg/kg (P = 0.0004) (Figure 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cleaved caspase-3 staining of tumor sections showed a significant increase in the percentage of cleaved caspase-3–positive cells in the metixene-treated groups at 0.1 mg/kg (P = 0.001) and 1.0 mg/kg (P = 0.0002) (Figure 2, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The treatment regimen involved intraperitoneal administration 3 times per week (Figure 2G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "While the control mice had a median survival of 31 days, the mice receiving metixene had a significantly extended median survival of 38 days (P = 0.0197) (Figure 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Furthermore, we observed no discernible tumor formation in the stomach or liver of these treated mice (Supplemental Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subsequently, 500 μL blood was collected from each mouse, and their brain tissues were harvested for analytical purposes (Figure 2I).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Metixene was completely cleared from the plasma within 3 hours of administration and from brain tissue within a 12-hour time frame (Figure 2J).Metixene improves in vivo survival in preclinical models of metastatic brain cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 10 days, the mice were randomized into 2 groups: control (25% captisol, n = 7) and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times a week (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The metixene-treated mice had a 23% increase in median survival, with a median survival period of 64 days, in contrast to the median survival of 52 days for the control mice (P = 0.0008) (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This finding was consistent with the measurement of the luciferase signal in the brain when the BT-474Br cells were fluorescently labeled and treated with metixene relative to controls after 6 weeks of treatment (P = 0.039) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of the brains of treated mice confirmed that metixene significantly induced caspase-3 cleavage in the established HER2-positive BCBMs in vivo (Figure 3D and Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Ten days after injection of tumor cells, the mice were randomized into 2 groups: control (25% captisol, n = 5) and metixene (1.0 mg/kg, n = 6) and were treated intraperitoneally 3 times per week (Figure 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Therefore, metixene significantly increased survival by 52% in comparison with controls (P = 0.037) (Figure 3F).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological examination of the brains harvested from control-treated mice showed multiple metastases, vascular co-option, and the formation of micrometastases (Figure 3G).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological comparison of brains of control and metixene treated mice showed a decreased tumor burden in the metixene-treated mice (Supplemental Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining showed that cleaved caspase-3 was significantly higher in the BCBM tissue of the metixene-treated mice in vivo (Figure 3H and Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel H",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The difference in body weight of treated and control mice was not significant (Supplemental Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Evaluation of organ tissue, such as the brain, heart, lung, liver, pancreas, kidneys, spleen, stomach, and intestines, revealed no differences in weight or anatomical architecture between the treated and untreated mice (Supplemental Figure 6, B and C).Metixene induces cellular stress and activates macroautophagy signaling pathways.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "RNA levels of either muscarinic (M1–M5) or histamine (H3) receptors did not correlate with the induced cytotoxicity of metixene (Supplemental Figure 7), indicating that the anticancer activity of metixene was not a function of muscarinic or histaminic receptors.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As such, to identify in an unbiased fashion the underlying mechanism of action of metixene, we treated BT-474Br cells with metixene and conducted a reverse-phase protein array (RPPA) analysis to assess the changes in signaling pathways (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Four replicates for each condition (control, 12 hours, and 24 hours) were analyzed and revealed that autophagy is a primary biological mechanism regulated by metixene (P < 0.05) (Figure 4B and Supplemental Figure 8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Among the proteins that exhibited significant changes (with P < 0.001) in expression or phosphorylation, 52 and 26 proteins, respectively were significantly altered (Figure 4, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Other proteins implicated in DNA damage and repair, P53, and cell-cycle control pathways were also affected, indicating cellular stress induction as a result of metixene treatment (Figure 4, E and F, and Supplemental Tables 1 and 2).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Conversion of LC3I to LC3II was shown to increase as early as 10 minutes after metixene treatment (Figure 5A).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Cells treated with the combination of metixene and chloroquine had higher LC3II levels than levels detected in the untreated cells or in the cells treated with either agent alone (Figure 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "This finding was further confirmed with immunofluorescence staining for LC3 (Figure 5C).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Quantification of the area of LC3 puncta per cell showed a significant increase (P < 0.05) upon the addition of chloroquine to metixene in both BT-474Br and MDA-MB-231Br cells (Figure 5, D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunofluorescence staining for LC3 in metixene-treated cells in a dose-dependent manner also showed a significant increase in the area of LC3 puncta per cell as the dose was increased in 2 BCBM cell lines (Supplemental Figure 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The addition of wortmannin, a PI3K inhibitor and an early inhibitor of autophagy flux (24), to metixene led to a decrease in LC3II expression (Supplemental Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "Using a system in which LC3, the marker of autophagosomes, is fused to both GFP and mCherry, we found that metixene-treated BT-474Br and MDA-MB-231 cells contained numerous autophagosomes (yellow/green), which do not bind to lysosomes that degrade their contents (red) (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Electron microscopic analysis of metixene-treated cells at 10 μM showed accumulation of double-membraned autophagic vesicles in the cytoplasm of BT-474Br and MDA-MB-231Br cells (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Similar results were confirmed in primary breast cancer cell lines (Supplemental Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Furthermore, the levels of p62, an autophagy cargo protein that binds other proteins for selective autophagy, increased significantly in BT-474Br (P = 0.0033) and MDA-MB-231Br (P = 0.0043) cells, indicating that the content of autophagic vesicles was not being degraded and that autophagy was incomplete (Figure 6C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of brain samples from control and metixene-treated mice showed that LC3B was significantly higher in metixene-treated samples in both BT-474Br intracranial models and MDA-MB-231Br intracarotid injection models (Figure 6, D and E, and Supplemental Figure 12).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel A",
          "figure_key": "figure_12"
        },
        {
          "figure_number": "Figure 12",
          "panel": "Panel B",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "The expression of NDRG1 and its phosphorylated form, p-NDRG1, increased significantly in a dose-dependent manner in both BT-474Br and MDA-MB-231Br cells after treatment with metixene (Figure 7, A and B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, the significant decrease in p62 levels in NDRG1-KO cells at 5 μM (P = 0.0014), 10 μM (P < 0.0001), and 15 μM (P = 0.0073) indicated that autophagy was being completed in comparison with NDRG1 VC cells (Figure 7C).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "The results showed that NDRG1-KO cells were significantly more viable than control cells at 20 μM (P < 0.0001) (Figure 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay further confirmed that apoptosis was significantly reduced in the NDRG1-KO cells at 10 μM (P = 0.0078) and 15 μM (P < 0.0001) (Figure 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Incomplete autophagy, as indicated by LC3I-to-LC3II conversion and accumulation of p62, preceded NDRG1 phosphorylation and eventual caspase-3 cleavage (Figure 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining for p-NDRG1 in murine brain samples showed that metixene treatment led to significantly higher expression of p-NDRG1 than in control samples (Figure 7G and Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This mechanism of action was consistent in other types of metastatic brain cancer, such as lung cancer and melanoma (Supplemental Figure 14).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We found that stem cell markers, such as SOX2 and OCT4, were downregulated after metixene treatment (Supplemental Figure 15).Discussion\nThe current management of patients with metastatic brain cancer typically includes resection and/or radiation, with a median survival of less than 14 months (27).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "In our work, we found that metixene upregulated NDRG1 expression and phosphorylation, which led to metastasis suppression through incomplete autophagy and apoptosis (Supplemental Figure 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "We found that metixene was a potent inhibitor of BCBM regardless of breast cancer subtype, with an IC50 ranging from 9.7 μM to 31.8 μM (Table 2 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI161142DS1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After both 24 and 48 hours of treatment, a dose response was evident in cellular viability assays for both cell lines (Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Flow cytometry results indicated that metixene was inducing cell death in cancer cells (Supplemental Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay was performed to check for caspase-mediated apoptosis, which showed a significant increase in activity that was dependent on dose and time in the BT-474Br and MDA-MB-231Br cells (Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We performed immunofluorescence studies to confirm that metixene induced caspase-3 cleavage in the 2 BCBM cell lines (Figure 1, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After 24 hours, we found that caspase-9 activity was significantly elevated at 10 μM in the BT-474Br cells (P = 0.0055), and at 15 μM in the BT-474Br cells (P < 0.0001) and the MDA-MB-231Br cells (P < 0.0001) (Figure 1, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "When the tumors reached 5 mm in size, the mice were randomized into 3 groups: control (25% captisol, n = 12), metixene (0.1 mg/kg, n = 8), and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times per week (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 6 weeks, the fat pad tumors were collected and analyzed (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor weights were significantly decreased with metixene treatment at 0.1 mg/kg (P < 0.0001) and 1.0 mg/kg (P < 0.0001) (Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor volumes were also significantly reduced with metixene treatment at 0.1 mg/kg (P = 0.0043) and 1.0 mg/kg (P = 0.0004) (Figure 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cleaved caspase-3 staining of tumor sections showed a significant increase in the percentage of cleaved caspase-3–positive cells in the metixene-treated groups at 0.1 mg/kg (P = 0.001) and 1.0 mg/kg (P = 0.0002) (Figure 2, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The treatment regimen involved intraperitoneal administration 3 times per week (Figure 2G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "While the control mice had a median survival of 31 days, the mice receiving metixene had a significantly extended median survival of 38 days (P = 0.0197) (Figure 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Furthermore, we observed no discernible tumor formation in the stomach or liver of these treated mice (Supplemental Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subsequently, 500 μL blood was collected from each mouse, and their brain tissues were harvested for analytical purposes (Figure 2I).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Metixene was completely cleared from the plasma within 3 hours of administration and from brain tissue within a 12-hour time frame (Figure 2J).Metixene improves in vivo survival in preclinical models of metastatic brain cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 10 days, the mice were randomized into 2 groups: control (25% captisol, n = 7) and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times a week (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The metixene-treated mice had a 23% increase in median survival, with a median survival period of 64 days, in contrast to the median survival of 52 days for the control mice (P = 0.0008) (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This finding was consistent with the measurement of the luciferase signal in the brain when the BT-474Br cells were fluorescently labeled and treated with metixene relative to controls after 6 weeks of treatment (P = 0.039) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of the brains of treated mice confirmed that metixene significantly induced caspase-3 cleavage in the established HER2-positive BCBMs in vivo (Figure 3D and Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Ten days after injection of tumor cells, the mice were randomized into 2 groups: control (25% captisol, n = 5) and metixene (1.0 mg/kg, n = 6) and were treated intraperitoneally 3 times per week (Figure 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Therefore, metixene significantly increased survival by 52% in comparison with controls (P = 0.037) (Figure 3F).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological examination of the brains harvested from control-treated mice showed multiple metastases, vascular co-option, and the formation of micrometastases (Figure 3G).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological comparison of brains of control and metixene treated mice showed a decreased tumor burden in the metixene-treated mice (Supplemental Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining showed that cleaved caspase-3 was significantly higher in the BCBM tissue of the metixene-treated mice in vivo (Figure 3H and Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel H",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The difference in body weight of treated and control mice was not significant (Supplemental Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Evaluation of organ tissue, such as the brain, heart, lung, liver, pancreas, kidneys, spleen, stomach, and intestines, revealed no differences in weight or anatomical architecture between the treated and untreated mice (Supplemental Figure 6, B and C).Metixene induces cellular stress and activates macroautophagy signaling pathways.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "RNA levels of either muscarinic (M1–M5) or histamine (H3) receptors did not correlate with the induced cytotoxicity of metixene (Supplemental Figure 7), indicating that the anticancer activity of metixene was not a function of muscarinic or histaminic receptors.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As such, to identify in an unbiased fashion the underlying mechanism of action of metixene, we treated BT-474Br cells with metixene and conducted a reverse-phase protein array (RPPA) analysis to assess the changes in signaling pathways (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Four replicates for each condition (control, 12 hours, and 24 hours) were analyzed and revealed that autophagy is a primary biological mechanism regulated by metixene (P < 0.05) (Figure 4B and Supplemental Figure 8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Among the proteins that exhibited significant changes (with P < 0.001) in expression or phosphorylation, 52 and 26 proteins, respectively were significantly altered (Figure 4, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Other proteins implicated in DNA damage and repair, P53, and cell-cycle control pathways were also affected, indicating cellular stress induction as a result of metixene treatment (Figure 4, E and F, and Supplemental Tables 1 and 2).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Conversion of LC3I to LC3II was shown to increase as early as 10 minutes after metixene treatment (Figure 5A).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Cells treated with the combination of metixene and chloroquine had higher LC3II levels than levels detected in the untreated cells or in the cells treated with either agent alone (Figure 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "This finding was further confirmed with immunofluorescence staining for LC3 (Figure 5C).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Quantification of the area of LC3 puncta per cell showed a significant increase (P < 0.05) upon the addition of chloroquine to metixene in both BT-474Br and MDA-MB-231Br cells (Figure 5, D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunofluorescence staining for LC3 in metixene-treated cells in a dose-dependent manner also showed a significant increase in the area of LC3 puncta per cell as the dose was increased in 2 BCBM cell lines (Supplemental Figure 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The addition of wortmannin, a PI3K inhibitor and an early inhibitor of autophagy flux (24), to metixene led to a decrease in LC3II expression (Supplemental Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "Using a system in which LC3, the marker of autophagosomes, is fused to both GFP and mCherry, we found that metixene-treated BT-474Br and MDA-MB-231 cells contained numerous autophagosomes (yellow/green), which do not bind to lysosomes that degrade their contents (red) (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Electron microscopic analysis of metixene-treated cells at 10 μM showed accumulation of double-membraned autophagic vesicles in the cytoplasm of BT-474Br and MDA-MB-231Br cells (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Similar results were confirmed in primary breast cancer cell lines (Supplemental Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Furthermore, the levels of p62, an autophagy cargo protein that binds other proteins for selective autophagy, increased significantly in BT-474Br (P = 0.0033) and MDA-MB-231Br (P = 0.0043) cells, indicating that the content of autophagic vesicles was not being degraded and that autophagy was incomplete (Figure 6C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of brain samples from control and metixene-treated mice showed that LC3B was significantly higher in metixene-treated samples in both BT-474Br intracranial models and MDA-MB-231Br intracarotid injection models (Figure 6, D and E, and Supplemental Figure 12).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel A",
          "figure_key": "figure_12"
        },
        {
          "figure_number": "Figure 12",
          "panel": "Panel B",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "The expression of NDRG1 and its phosphorylated form, p-NDRG1, increased significantly in a dose-dependent manner in both BT-474Br and MDA-MB-231Br cells after treatment with metixene (Figure 7, A and B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, the significant decrease in p62 levels in NDRG1-KO cells at 5 μM (P = 0.0014), 10 μM (P < 0.0001), and 15 μM (P = 0.0073) indicated that autophagy was being completed in comparison with NDRG1 VC cells (Figure 7C).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "The results showed that NDRG1-KO cells were significantly more viable than control cells at 20 μM (P < 0.0001) (Figure 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay further confirmed that apoptosis was significantly reduced in the NDRG1-KO cells at 10 μM (P = 0.0078) and 15 μM (P < 0.0001) (Figure 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Incomplete autophagy, as indicated by LC3I-to-LC3II conversion and accumulation of p62, preceded NDRG1 phosphorylation and eventual caspase-3 cleavage (Figure 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining for p-NDRG1 in murine brain samples showed that metixene treatment led to significantly higher expression of p-NDRG1 than in control samples (Figure 7G and Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This mechanism of action was consistent in other types of metastatic brain cancer, such as lung cancer and melanoma (Supplemental Figure 14).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We found that stem cell markers, such as SOX2 and OCT4, were downregulated after metixene treatment (Supplemental Figure 15).Discussion\nThe current management of patients with metastatic brain cancer typically includes resection and/or radiation, with a median survival of less than 14 months (27).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "In our work, we found that metixene upregulated NDRG1 expression and phosphorylation, which led to metastasis suppression through incomplete autophagy and apoptosis (Supplemental Figure 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "We found that metixene was a potent inhibitor of BCBM regardless of breast cancer subtype, with an IC50 ranging from 9.7 μM to 31.8 μM (Table 2 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI161142DS1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After both 24 and 48 hours of treatment, a dose response was evident in cellular viability assays for both cell lines (Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Flow cytometry results indicated that metixene was inducing cell death in cancer cells (Supplemental Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay was performed to check for caspase-mediated apoptosis, which showed a significant increase in activity that was dependent on dose and time in the BT-474Br and MDA-MB-231Br cells (Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We performed immunofluorescence studies to confirm that metixene induced caspase-3 cleavage in the 2 BCBM cell lines (Figure 1, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After 24 hours, we found that caspase-9 activity was significantly elevated at 10 μM in the BT-474Br cells (P = 0.0055), and at 15 μM in the BT-474Br cells (P < 0.0001) and the MDA-MB-231Br cells (P < 0.0001) (Figure 1, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "When the tumors reached 5 mm in size, the mice were randomized into 3 groups: control (25% captisol, n = 12), metixene (0.1 mg/kg, n = 8), and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times per week (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 6 weeks, the fat pad tumors were collected and analyzed (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor weights were significantly decreased with metixene treatment at 0.1 mg/kg (P < 0.0001) and 1.0 mg/kg (P < 0.0001) (Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor volumes were also significantly reduced with metixene treatment at 0.1 mg/kg (P = 0.0043) and 1.0 mg/kg (P = 0.0004) (Figure 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cleaved caspase-3 staining of tumor sections showed a significant increase in the percentage of cleaved caspase-3–positive cells in the metixene-treated groups at 0.1 mg/kg (P = 0.001) and 1.0 mg/kg (P = 0.0002) (Figure 2, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The treatment regimen involved intraperitoneal administration 3 times per week (Figure 2G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "While the control mice had a median survival of 31 days, the mice receiving metixene had a significantly extended median survival of 38 days (P = 0.0197) (Figure 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Furthermore, we observed no discernible tumor formation in the stomach or liver of these treated mice (Supplemental Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subsequently, 500 μL blood was collected from each mouse, and their brain tissues were harvested for analytical purposes (Figure 2I).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Metixene was completely cleared from the plasma within 3 hours of administration and from brain tissue within a 12-hour time frame (Figure 2J).Metixene improves in vivo survival in preclinical models of metastatic brain cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 10 days, the mice were randomized into 2 groups: control (25% captisol, n = 7) and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times a week (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The metixene-treated mice had a 23% increase in median survival, with a median survival period of 64 days, in contrast to the median survival of 52 days for the control mice (P = 0.0008) (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This finding was consistent with the measurement of the luciferase signal in the brain when the BT-474Br cells were fluorescently labeled and treated with metixene relative to controls after 6 weeks of treatment (P = 0.039) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of the brains of treated mice confirmed that metixene significantly induced caspase-3 cleavage in the established HER2-positive BCBMs in vivo (Figure 3D and Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Ten days after injection of tumor cells, the mice were randomized into 2 groups: control (25% captisol, n = 5) and metixene (1.0 mg/kg, n = 6) and were treated intraperitoneally 3 times per week (Figure 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Therefore, metixene significantly increased survival by 52% in comparison with controls (P = 0.037) (Figure 3F).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological examination of the brains harvested from control-treated mice showed multiple metastases, vascular co-option, and the formation of micrometastases (Figure 3G).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological comparison of brains of control and metixene treated mice showed a decreased tumor burden in the metixene-treated mice (Supplemental Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining showed that cleaved caspase-3 was significantly higher in the BCBM tissue of the metixene-treated mice in vivo (Figure 3H and Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel H",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The difference in body weight of treated and control mice was not significant (Supplemental Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Evaluation of organ tissue, such as the brain, heart, lung, liver, pancreas, kidneys, spleen, stomach, and intestines, revealed no differences in weight or anatomical architecture between the treated and untreated mice (Supplemental Figure 6, B and C).Metixene induces cellular stress and activates macroautophagy signaling pathways.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "RNA levels of either muscarinic (M1–M5) or histamine (H3) receptors did not correlate with the induced cytotoxicity of metixene (Supplemental Figure 7), indicating that the anticancer activity of metixene was not a function of muscarinic or histaminic receptors.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As such, to identify in an unbiased fashion the underlying mechanism of action of metixene, we treated BT-474Br cells with metixene and conducted a reverse-phase protein array (RPPA) analysis to assess the changes in signaling pathways (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Four replicates for each condition (control, 12 hours, and 24 hours) were analyzed and revealed that autophagy is a primary biological mechanism regulated by metixene (P < 0.05) (Figure 4B and Supplemental Figure 8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Among the proteins that exhibited significant changes (with P < 0.001) in expression or phosphorylation, 52 and 26 proteins, respectively were significantly altered (Figure 4, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Other proteins implicated in DNA damage and repair, P53, and cell-cycle control pathways were also affected, indicating cellular stress induction as a result of metixene treatment (Figure 4, E and F, and Supplemental Tables 1 and 2).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Conversion of LC3I to LC3II was shown to increase as early as 10 minutes after metixene treatment (Figure 5A).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Cells treated with the combination of metixene and chloroquine had higher LC3II levels than levels detected in the untreated cells or in the cells treated with either agent alone (Figure 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "This finding was further confirmed with immunofluorescence staining for LC3 (Figure 5C).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Quantification of the area of LC3 puncta per cell showed a significant increase (P < 0.05) upon the addition of chloroquine to metixene in both BT-474Br and MDA-MB-231Br cells (Figure 5, D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunofluorescence staining for LC3 in metixene-treated cells in a dose-dependent manner also showed a significant increase in the area of LC3 puncta per cell as the dose was increased in 2 BCBM cell lines (Supplemental Figure 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The addition of wortmannin, a PI3K inhibitor and an early inhibitor of autophagy flux (24), to metixene led to a decrease in LC3II expression (Supplemental Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "Using a system in which LC3, the marker of autophagosomes, is fused to both GFP and mCherry, we found that metixene-treated BT-474Br and MDA-MB-231 cells contained numerous autophagosomes (yellow/green), which do not bind to lysosomes that degrade their contents (red) (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Electron microscopic analysis of metixene-treated cells at 10 μM showed accumulation of double-membraned autophagic vesicles in the cytoplasm of BT-474Br and MDA-MB-231Br cells (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Similar results were confirmed in primary breast cancer cell lines (Supplemental Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Furthermore, the levels of p62, an autophagy cargo protein that binds other proteins for selective autophagy, increased significantly in BT-474Br (P = 0.0033) and MDA-MB-231Br (P = 0.0043) cells, indicating that the content of autophagic vesicles was not being degraded and that autophagy was incomplete (Figure 6C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of brain samples from control and metixene-treated mice showed that LC3B was significantly higher in metixene-treated samples in both BT-474Br intracranial models and MDA-MB-231Br intracarotid injection models (Figure 6, D and E, and Supplemental Figure 12).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel A",
          "figure_key": "figure_12"
        },
        {
          "figure_number": "Figure 12",
          "panel": "Panel B",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "The expression of NDRG1 and its phosphorylated form, p-NDRG1, increased significantly in a dose-dependent manner in both BT-474Br and MDA-MB-231Br cells after treatment with metixene (Figure 7, A and B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, the significant decrease in p62 levels in NDRG1-KO cells at 5 μM (P = 0.0014), 10 μM (P < 0.0001), and 15 μM (P = 0.0073) indicated that autophagy was being completed in comparison with NDRG1 VC cells (Figure 7C).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "The results showed that NDRG1-KO cells were significantly more viable than control cells at 20 μM (P < 0.0001) (Figure 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay further confirmed that apoptosis was significantly reduced in the NDRG1-KO cells at 10 μM (P = 0.0078) and 15 μM (P < 0.0001) (Figure 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Incomplete autophagy, as indicated by LC3I-to-LC3II conversion and accumulation of p62, preceded NDRG1 phosphorylation and eventual caspase-3 cleavage (Figure 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining for p-NDRG1 in murine brain samples showed that metixene treatment led to significantly higher expression of p-NDRG1 than in control samples (Figure 7G and Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This mechanism of action was consistent in other types of metastatic brain cancer, such as lung cancer and melanoma (Supplemental Figure 14).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We found that stem cell markers, such as SOX2 and OCT4, were downregulated after metixene treatment (Supplemental Figure 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "We found that metixene was a potent inhibitor of BCBM regardless of breast cancer subtype, with an IC50 ranging from 9.7 μM to 31.8 μM (Table 2 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI161142DS1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After both 24 and 48 hours of treatment, a dose response was evident in cellular viability assays for both cell lines (Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We found that metixene was a potent inhibitor of BCBM regardless of breast cancer subtype, with an IC50 ranging from 9.7 μM to 31.8 μM (Table 2 and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI161142DS1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After both 24 and 48 hours of treatment, a dose response was evident in cellular viability assays for both cell lines (Figure 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Flow cytometry results indicated that metixene was inducing cell death in cancer cells (Supplemental Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay was performed to check for caspase-mediated apoptosis, which showed a significant increase in activity that was dependent on dose and time in the BT-474Br and MDA-MB-231Br cells (Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We performed immunofluorescence studies to confirm that metixene induced caspase-3 cleavage in the 2 BCBM cell lines (Figure 1, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After 24 hours, we found that caspase-9 activity was significantly elevated at 10 μM in the BT-474Br cells (P = 0.0055), and at 15 μM in the BT-474Br cells (P < 0.0001) and the MDA-MB-231Br cells (P < 0.0001) (Figure 1, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Flow cytometry results indicated that metixene was inducing cell death in cancer cells (Supplemental Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay was performed to check for caspase-mediated apoptosis, which showed a significant increase in activity that was dependent on dose and time in the BT-474Br and MDA-MB-231Br cells (Figure 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We performed immunofluorescence studies to confirm that metixene induced caspase-3 cleavage in the 2 BCBM cell lines (Figure 1, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "After 24 hours, we found that caspase-9 activity was significantly elevated at 10 μM in the BT-474Br cells (P = 0.0055), and at 15 μM in the BT-474Br cells (P < 0.0001) and the MDA-MB-231Br cells (P < 0.0001) (Figure 1, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "When the tumors reached 5 mm in size, the mice were randomized into 3 groups: control (25% captisol, n = 12), metixene (0.1 mg/kg, n = 8), and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times per week (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 6 weeks, the fat pad tumors were collected and analyzed (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor weights were significantly decreased with metixene treatment at 0.1 mg/kg (P < 0.0001) and 1.0 mg/kg (P < 0.0001) (Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor volumes were also significantly reduced with metixene treatment at 0.1 mg/kg (P = 0.0043) and 1.0 mg/kg (P = 0.0004) (Figure 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cleaved caspase-3 staining of tumor sections showed a significant increase in the percentage of cleaved caspase-3–positive cells in the metixene-treated groups at 0.1 mg/kg (P = 0.001) and 1.0 mg/kg (P = 0.0002) (Figure 2, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The treatment regimen involved intraperitoneal administration 3 times per week (Figure 2G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "While the control mice had a median survival of 31 days, the mice receiving metixene had a significantly extended median survival of 38 days (P = 0.0197) (Figure 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Furthermore, we observed no discernible tumor formation in the stomach or liver of these treated mice (Supplemental Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subsequently, 500 μL blood was collected from each mouse, and their brain tissues were harvested for analytical purposes (Figure 2I).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Metixene was completely cleared from the plasma within 3 hours of administration and from brain tissue within a 12-hour time frame (Figure 2J).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "When the tumors reached 5 mm in size, the mice were randomized into 3 groups: control (25% captisol, n = 12), metixene (0.1 mg/kg, n = 8), and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times per week (Figure 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 6 weeks, the fat pad tumors were collected and analyzed (Figure 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor weights were significantly decreased with metixene treatment at 0.1 mg/kg (P < 0.0001) and 1.0 mg/kg (P < 0.0001) (Figure 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Tumor volumes were also significantly reduced with metixene treatment at 0.1 mg/kg (P = 0.0043) and 1.0 mg/kg (P = 0.0004) (Figure 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Cleaved caspase-3 staining of tumor sections showed a significant increase in the percentage of cleaved caspase-3–positive cells in the metixene-treated groups at 0.1 mg/kg (P = 0.001) and 1.0 mg/kg (P = 0.0002) (Figure 2, E and F).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The treatment regimen involved intraperitoneal administration 3 times per week (Figure 2G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "While the control mice had a median survival of 31 days, the mice receiving metixene had a significantly extended median survival of 38 days (P = 0.0197) (Figure 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Furthermore, we observed no discernible tumor formation in the stomach or liver of these treated mice (Supplemental Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Subsequently, 500 μL blood was collected from each mouse, and their brain tissues were harvested for analytical purposes (Figure 2I).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel I",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Metixene was completely cleared from the plasma within 3 hours of administration and from brain tissue within a 12-hour time frame (Figure 2J).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel J",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "After 10 days, the mice were randomized into 2 groups: control (25% captisol, n = 7) and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times a week (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The metixene-treated mice had a 23% increase in median survival, with a median survival period of 64 days, in contrast to the median survival of 52 days for the control mice (P = 0.0008) (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This finding was consistent with the measurement of the luciferase signal in the brain when the BT-474Br cells were fluorescently labeled and treated with metixene relative to controls after 6 weeks of treatment (P = 0.039) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of the brains of treated mice confirmed that metixene significantly induced caspase-3 cleavage in the established HER2-positive BCBMs in vivo (Figure 3D and Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Ten days after injection of tumor cells, the mice were randomized into 2 groups: control (25% captisol, n = 5) and metixene (1.0 mg/kg, n = 6) and were treated intraperitoneally 3 times per week (Figure 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Therefore, metixene significantly increased survival by 52% in comparison with controls (P = 0.037) (Figure 3F).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological examination of the brains harvested from control-treated mice showed multiple metastases, vascular co-option, and the formation of micrometastases (Figure 3G).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological comparison of brains of control and metixene treated mice showed a decreased tumor burden in the metixene-treated mice (Supplemental Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining showed that cleaved caspase-3 was significantly higher in the BCBM tissue of the metixene-treated mice in vivo (Figure 3H and Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel H",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The difference in body weight of treated and control mice was not significant (Supplemental Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Evaluation of organ tissue, such as the brain, heart, lung, liver, pancreas, kidneys, spleen, stomach, and intestines, revealed no differences in weight or anatomical architecture between the treated and untreated mice (Supplemental Figure 6, B and C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "After 10 days, the mice were randomized into 2 groups: control (25% captisol, n = 7) and metixene (1.0 mg/kg, n = 8), and were treated intraperitoneally 3 times a week (Figure 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The metixene-treated mice had a 23% increase in median survival, with a median survival period of 64 days, in contrast to the median survival of 52 days for the control mice (P = 0.0008) (Figure 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "This finding was consistent with the measurement of the luciferase signal in the brain when the BT-474Br cells were fluorescently labeled and treated with metixene relative to controls after 6 weeks of treatment (P = 0.039) (Figure 3C).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of the brains of treated mice confirmed that metixene significantly induced caspase-3 cleavage in the established HER2-positive BCBMs in vivo (Figure 3D and Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "(A) Experimental setup for stereotactic intracranial injection of BT-474Br cells into the brains of nude mice and subsequent treatment with metixene. (B) Kaplan-Meier curve showing survival of metixene-treated mice versus survival of control mice upon intracranial injection of BT-474Br cells. (C) Bioluminescence imaging of the 2 groups (control vs. treated) across time. (D) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Scale bars: 2.5 mm; 100 μm, and 500 μm. (H) Immunohistochemical staining for cleaved caspase-3 in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Ten days after injection of tumor cells, the mice were randomized into 2 groups: control (25% captisol, n = 5) and metixene (1.0 mg/kg, n = 6) and were treated intraperitoneally 3 times per week (Figure 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Therefore, metixene significantly increased survival by 52% in comparison with controls (P = 0.037) (Figure 3F).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological examination of the brains harvested from control-treated mice showed multiple metastases, vascular co-option, and the formation of micrometastases (Figure 3G).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Histological comparison of brains of control and metixene treated mice showed a decreased tumor burden in the metixene-treated mice (Supplemental Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining showed that cleaved caspase-3 was significantly higher in the BCBM tissue of the metixene-treated mice in vivo (Figure 3H and Supplemental Figure 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel H",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The difference in body weight of treated and control mice was not significant (Supplemental Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Evaluation of organ tissue, such as the brain, heart, lung, liver, pancreas, kidneys, spleen, stomach, and intestines, revealed no differences in weight or anatomical architecture between the treated and untreated mice (Supplemental Figure 6, B and C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "RNA levels of either muscarinic (M1–M5) or histamine (H3) receptors did not correlate with the induced cytotoxicity of metixene (Supplemental Figure 7), indicating that the anticancer activity of metixene was not a function of muscarinic or histaminic receptors.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As such, to identify in an unbiased fashion the underlying mechanism of action of metixene, we treated BT-474Br cells with metixene and conducted a reverse-phase protein array (RPPA) analysis to assess the changes in signaling pathways (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Four replicates for each condition (control, 12 hours, and 24 hours) were analyzed and revealed that autophagy is a primary biological mechanism regulated by metixene (P < 0.05) (Figure 4B and Supplemental Figure 8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Among the proteins that exhibited significant changes (with P < 0.001) in expression or phosphorylation, 52 and 26 proteins, respectively were significantly altered (Figure 4, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Other proteins implicated in DNA damage and repair, P53, and cell-cycle control pathways were also affected, indicating cellular stress induction as a result of metixene treatment (Figure 4, E and F, and Supplemental Tables 1 and 2).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Conversion of LC3I to LC3II was shown to increase as early as 10 minutes after metixene treatment (Figure 5A).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Cells treated with the combination of metixene and chloroquine had higher LC3II levels than levels detected in the untreated cells or in the cells treated with either agent alone (Figure 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "This finding was further confirmed with immunofluorescence staining for LC3 (Figure 5C).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Quantification of the area of LC3 puncta per cell showed a significant increase (P < 0.05) upon the addition of chloroquine to metixene in both BT-474Br and MDA-MB-231Br cells (Figure 5, D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunofluorescence staining for LC3 in metixene-treated cells in a dose-dependent manner also showed a significant increase in the area of LC3 puncta per cell as the dose was increased in 2 BCBM cell lines (Supplemental Figure 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The addition of wortmannin, a PI3K inhibitor and an early inhibitor of autophagy flux (24), to metixene led to a decrease in LC3II expression (Supplemental Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "RNA levels of either muscarinic (M1–M5) or histamine (H3) receptors did not correlate with the induced cytotoxicity of metixene (Supplemental Figure 7), indicating that the anticancer activity of metixene was not a function of muscarinic or histaminic receptors.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As such, to identify in an unbiased fashion the underlying mechanism of action of metixene, we treated BT-474Br cells with metixene and conducted a reverse-phase protein array (RPPA) analysis to assess the changes in signaling pathways (Figure 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Four replicates for each condition (control, 12 hours, and 24 hours) were analyzed and revealed that autophagy is a primary biological mechanism regulated by metixene (P < 0.05) (Figure 4B and Supplemental Figure 8).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Among the proteins that exhibited significant changes (with P < 0.001) in expression or phosphorylation, 52 and 26 proteins, respectively were significantly altered (Figure 4, C and D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Other proteins implicated in DNA damage and repair, P53, and cell-cycle control pathways were also affected, indicating cellular stress induction as a result of metixene treatment (Figure 4, E and F, and Supplemental Tables 1 and 2).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Conversion of LC3I to LC3II was shown to increase as early as 10 minutes after metixene treatment (Figure 5A).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Cells treated with the combination of metixene and chloroquine had higher LC3II levels than levels detected in the untreated cells or in the cells treated with either agent alone (Figure 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "This finding was further confirmed with immunofluorescence staining for LC3 (Figure 5C).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Quantification of the area of LC3 puncta per cell showed a significant increase (P < 0.05) upon the addition of chloroquine to metixene in both BT-474Br and MDA-MB-231Br cells (Figure 5, D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Immunofluorescence staining for LC3 in metixene-treated cells in a dose-dependent manner also showed a significant increase in the area of LC3 puncta per cell as the dose was increased in 2 BCBM cell lines (Supplemental Figure 9).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The addition of wortmannin, a PI3K inhibitor and an early inhibitor of autophagy flux (24), to metixene led to a decrease in LC3II expression (Supplemental Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "Using a system in which LC3, the marker of autophagosomes, is fused to both GFP and mCherry, we found that metixene-treated BT-474Br and MDA-MB-231 cells contained numerous autophagosomes (yellow/green), which do not bind to lysosomes that degrade their contents (red) (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Electron microscopic analysis of metixene-treated cells at 10 μM showed accumulation of double-membraned autophagic vesicles in the cytoplasm of BT-474Br and MDA-MB-231Br cells (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Similar results were confirmed in primary breast cancer cell lines (Supplemental Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Furthermore, the levels of p62, an autophagy cargo protein that binds other proteins for selective autophagy, increased significantly in BT-474Br (P = 0.0033) and MDA-MB-231Br (P = 0.0043) cells, indicating that the content of autophagic vesicles was not being degraded and that autophagy was incomplete (Figure 6C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of brain samples from control and metixene-treated mice showed that LC3B was significantly higher in metixene-treated samples in both BT-474Br intracranial models and MDA-MB-231Br intracarotid injection models (Figure 6, D and E, and Supplemental Figure 12).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel A",
          "figure_key": "figure_12"
        },
        {
          "figure_number": "Figure 12",
          "panel": "Panel B",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Using a system in which LC3, the marker of autophagosomes, is fused to both GFP and mCherry, we found that metixene-treated BT-474Br and MDA-MB-231 cells contained numerous autophagosomes (yellow/green), which do not bind to lysosomes that degrade their contents (red) (Figure 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Electron microscopic analysis of metixene-treated cells at 10 μM showed accumulation of double-membraned autophagic vesicles in the cytoplasm of BT-474Br and MDA-MB-231Br cells (Figure 6B).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Similar results were confirmed in primary breast cancer cell lines (Supplemental Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Furthermore, the levels of p62, an autophagy cargo protein that binds other proteins for selective autophagy, increased significantly in BT-474Br (P = 0.0033) and MDA-MB-231Br (P = 0.0043) cells, indicating that the content of autophagic vesicles was not being degraded and that autophagy was incomplete (Figure 6C).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining of brain samples from control and metixene-treated mice showed that LC3B was significantly higher in metixene-treated samples in both BT-474Br intracranial models and MDA-MB-231Br intracarotid injection models (Figure 6, D and E, and Supplemental Figure 12).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Scale bars: 5 μm (top left), 1 μm (enlarged insets, top right) and 500 nm (bottom left), 100 nm (enlarged insets, bottom right). (C) Western blots and analysis of LC3 and p62 protein expression in BT-474Br and MDA-MB-231Br cells treated with increasing concentrations of metixene (μM) for 48 hours. (D) Immunohistochemical staining for LC3B in brain samples of control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 12A). (E) Immunohistochemical staining for LC3B in brain samples from control and metixene-treated mice bearing MDA-MB-231Br tumors (quantification of the stained area is shown in Supplemental Figure 12B).",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "Panel A",
          "figure_key": "figure_12"
        },
        {
          "figure_number": "Figure 12",
          "panel": "Panel B",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "The expression of NDRG1 and its phosphorylated form, p-NDRG1, increased significantly in a dose-dependent manner in both BT-474Br and MDA-MB-231Br cells after treatment with metixene (Figure 7, A and B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, the significant decrease in p62 levels in NDRG1-KO cells at 5 μM (P = 0.0014), 10 μM (P < 0.0001), and 15 μM (P = 0.0073) indicated that autophagy was being completed in comparison with NDRG1 VC cells (Figure 7C).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\n(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "The results showed that NDRG1-KO cells were significantly more viable than control cells at 20 μM (P < 0.0001) (Figure 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay further confirmed that apoptosis was significantly reduced in the NDRG1-KO cells at 10 μM (P = 0.0078) and 15 μM (P < 0.0001) (Figure 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Incomplete autophagy, as indicated by LC3I-to-LC3II conversion and accumulation of p62, preceded NDRG1 phosphorylation and eventual caspase-3 cleavage (Figure 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining for p-NDRG1 in murine brain samples showed that metixene treatment led to significantly higher expression of p-NDRG1 than in control samples (Figure 7G and Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This mechanism of action was consistent in other types of metastatic brain cancer, such as lung cancer and melanoma (Supplemental Figure 14).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We found that stem cell markers, such as SOX2 and OCT4, were downregulated after metixene treatment (Supplemental Figure 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "The expression of NDRG1 and its phosphorylated form, p-NDRG1, increased significantly in a dose-dependent manner in both BT-474Br and MDA-MB-231Br cells after treatment with metixene (Figure 7, A and B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, the significant decrease in p62 levels in NDRG1-KO cells at 5 μM (P = 0.0014), 10 μM (P < 0.0001), and 15 μM (P = 0.0073) indicated that autophagy was being completed in comparison with NDRG1 VC cells (Figure 7C).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "(A) Western blots and analysis p-NDRG1 and NDRG1 protein expression in BT-474Br cells treated with increasing concentrations of metixene (μM). (B) Western blots and analysis of p-NDRG1 and NDRG1 protein expression in MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (C) Western blots and analysis of protein expression in NDRG1-KO versus VC-transfected MDA-MB-231Br cells treated with increasing concentrations of metixene (μM). (D) Viability of NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (E) Caspase-3/-7 activity in NDRG1-KO versus VC-transfected MDA-MB-231Br cells under treatment with different concentrations of metixene for 24 hours. (F) Protein expression of LC3, p62, p-NDRG1, and cleaved caspase-3 in BT-474Br and MDA-MB-231Br cells treated with metixene in a time-dependent manner. (G) Immunohistochemical staining for p-NDRG1 in brain samples from control and metixene-treated mice bearing BT-474Br tumors (quantification of the stained area is shown in Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "The results showed that NDRG1-KO cells were significantly more viable than control cells at 20 μM (P < 0.0001) (Figure 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "A caspase-3/-7 assay further confirmed that apoptosis was significantly reduced in the NDRG1-KO cells at 10 μM (P = 0.0078) and 15 μM (P < 0.0001) (Figure 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Incomplete autophagy, as indicated by LC3I-to-LC3II conversion and accumulation of p62, preceded NDRG1 phosphorylation and eventual caspase-3 cleavage (Figure 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Immunohistochemical staining for p-NDRG1 in murine brain samples showed that metixene treatment led to significantly higher expression of p-NDRG1 than in control samples (Figure 7G and Supplemental Figure 13).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 13",
          "panel": "",
          "figure_key": "figure_13"
        }
      ]
    },
    {
      "sentence": "This mechanism of action was consistent in other types of metastatic brain cancer, such as lung cancer and melanoma (Supplemental Figure 14).",
      "figure_references": [
        {
          "figure_number": "Figure 14",
          "panel": "",
          "figure_key": "figure_14"
        }
      ]
    },
    {
      "sentence": "We found that stem cell markers, such as SOX2 and OCT4, were downregulated after metixene treatment (Supplemental Figure 15).",
      "figure_references": [
        {
          "figure_number": "Figure 15",
          "panel": "",
          "figure_key": "figure_15"
        }
      ]
    },
    {
      "sentence": "In our work, we found that metixene upregulated NDRG1 expression and phosphorylation, which led to metastasis suppression through incomplete autophagy and apoptosis (Supplemental Figure 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    },
    {
      "sentence": "In our work, we found that metixene upregulated NDRG1 expression and phosphorylation, which led to metastasis suppression through incomplete autophagy and apoptosis (Supplemental Figure 16).",
      "figure_references": [
        {
          "figure_number": "Figure 16",
          "panel": "",
          "figure_key": "figure_16"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 5,
    "claims_count": 615,
    "images_downloaded": 5,
    "tables_filtered": 24
  }
}